199 related articles for article (PubMed ID: 16719778)
1. Choline kinase: an important target for cancer.
Janardhan S; Srivani P; Sastry GN
Curr Med Chem; 2006; 13(10):1169-86. PubMed ID: 16719778
[TBL] [Abstract][Full Text] [Related]
2. Choline kinase inhibitors as a novel approach for antiproliferative drug design.
Hernández-Alcoceba R; Saniger L; Campos J; Núñez MC; Khaless F; Gallo MA; Espinosa A; Lacal JC
Oncogene; 1997 Nov; 15(19):2289-301. PubMed ID: 9393874
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells.
Ramírez de Molina A; Rodríguez-González A; Penalva V; Lucas L; Lacal JC
Biochem Biophys Res Commun; 2001 Jul; 285(4):873-9. PubMed ID: 11467831
[TBL] [Abstract][Full Text] [Related]
4. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K.
Ramírez de Molina A; Penalva V; Lucas L; Lacal JC
Oncogene; 2002 Jan; 21(6):937-46. PubMed ID: 11840339
[TBL] [Abstract][Full Text] [Related]
5. ChoK-ing the Pathogenic Bacteria: Potential of Human Choline Kinase Inhibitors as Antimicrobial Agents.
Khalifa M; Few LL; See Too WC
Biomed Res Int; 2020; 2020():1823485. PubMed ID: 32695809
[TBL] [Abstract][Full Text] [Related]
6. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action.
Rodríguez-González A; Ramirez de Molina A; Fernández F; Lacal JC
Oncogene; 2004 Oct; 23(50):8247-59. PubMed ID: 15378008
[TBL] [Abstract][Full Text] [Related]
7. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design.
Ramírez de Molina A; Rodríguez-González A; Lacal JC
Cancer Lett; 2004 Apr; 206(2):137-48. PubMed ID: 15013519
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of human choline kinase isoforms in complex with hemicholinium-3: single amino acid near the active site influences inhibitor sensitivity.
Hong BS; Allali-Hassani A; Tempel W; Finerty PJ; Mackenzie F; Dimov S; Vedadi M; Park HW
J Biol Chem; 2010 May; 285(21):16330-40. PubMed ID: 20299452
[TBL] [Abstract][Full Text] [Related]
9. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression.
Ramírez de Molina A; Báñez-Coronel M; Gutiérrez R; Rodríguez-González A; Olmeda D; Megías D; Lacal JC
Cancer Res; 2004 Sep; 64(18):6732-9. PubMed ID: 15374991
[TBL] [Abstract][Full Text] [Related]
10. Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
Granata A; Nicoletti R; Tinaglia V; De Cecco L; Pisanu ME; Ricci A; Podo F; Canevari S; Iorio E; Bagnoli M; Mezzanzanica D
Br J Cancer; 2014 Jan; 110(2):330-40. PubMed ID: 24281000
[TBL] [Abstract][Full Text] [Related]
11. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment.
Gallego-Ortega D; Ramirez de Molina A; Ramos MA; Valdes-Mora F; Barderas MG; Sarmentero-Estrada J; Lacal JC
PLoS One; 2009 Nov; 4(11):e7819. PubMed ID: 19915674
[TBL] [Abstract][Full Text] [Related]
12. QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be?
Campos J; Núñez MC; Conejo-García A; Sánchez-Martín RM; Hernández-Alcoceba R; Rodríguez-González A; Lacal JC; Gallo MA; Espinosa A
Curr Med Chem; 2003 Jul; 10(13):1095-112. PubMed ID: 12678804
[TBL] [Abstract][Full Text] [Related]
13. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.
Ramírez de Molina A; Gutiérrez R; Ramos MA; Silva JM; Silva J; Bonilla F; Sánchez JJ; Lacal JC
Oncogene; 2002 Jun; 21(27):4317-22. PubMed ID: 12082619
[TBL] [Abstract][Full Text] [Related]
14. Potential choline kinase inhibitors: a molecular modeling study of bis-quinolinium compounds.
Srivani P; Sastry GN
J Mol Graph Model; 2009 Feb; 27(6):676-88. PubMed ID: 19147382
[TBL] [Abstract][Full Text] [Related]
15. RAS-mediated oncogenic signaling pathways in human malignancies.
Khan AQ; Kuttikrishnan S; Siveen KS; Prabhu KS; Shanmugakonar M; Al-Naemi HA; Haris M; Dermime S; Uddin S
Semin Cancer Biol; 2019 Feb; 54():1-13. PubMed ID: 29524560
[TBL] [Abstract][Full Text] [Related]
16. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells.
Iorio E; Ricci A; Bagnoli M; Pisanu ME; Castellano G; Di Vito M; Venturini E; Glunde K; Bhujwalla ZM; Mezzanzanica D; Canevari S; Podo F
Cancer Res; 2010 Mar; 70(5):2126-35. PubMed ID: 20179205
[TBL] [Abstract][Full Text] [Related]
17. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy.
Al-Saffar NM; Jackson LE; Raynaud FI; Clarke PA; Ramírez de Molina A; Lacal JC; Workman P; Leach MO
Cancer Res; 2010 Jul; 70(13):5507-17. PubMed ID: 20551061
[TBL] [Abstract][Full Text] [Related]
18. Structure and function of choline kinase isoforms in mammalian cells.
Aoyama C; Liao H; Ishidate K
Prog Lipid Res; 2004 May; 43(3):266-81. PubMed ID: 15003397
[TBL] [Abstract][Full Text] [Related]
19. Direct inhibition of choline kinase by a near-infrared fluorescent carbocyanine.
Arlauckas SP; Popov AV; Delikatny EJ
Mol Cancer Ther; 2014 Sep; 13(9):2149-58. PubMed ID: 25028471
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells.
Rodríguez-González A; Ramírez de Molina A; Fernández F; Ramos MA; del Carmen Núñez M; Campos J; Lacal JC
Oncogene; 2003 Dec; 22(55):8803-12. PubMed ID: 14654777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
